ISOFOL — Isofol Medical AB (publ) Share News
0.000.00%
Last trade - 00:00- SEK198.74m
- SEK88.00m
Brief: Isofol Medical: COVID-19 Can Delay Patient Recruitment With 3 Months
Brief: Isofol's Rights Issue Oversubscribed
Brief: Isofol Medical Q1 Net Loss Widens To SEK 55.9 Million
Brief: Isofol Resolve On A Fully Guaranteed Preferential Rights Issue
Brief: Isofol: Arfolitixorin Gets Additional Clinical Patent Approval In US
Brief: Isofol Medical Postpones AGM
Brief: Isofol Medical: Information In Relation To COVID-19
Brief: Isofol Medical: More Patients To Benefit From Arfolitixorin
Brief: Isofol Intends To Carry Out Rights Issue Of SEK 150 Million
Brief: Isofol Medical Q4 Net loss SEK 57.9 mln
Brief: Isofol Medical: Gene Expression Analysis Method Validated By A Commercial Laboratory
Brief: Isofol Medical Completes Phase 1/2a Study ISO-CC-005
Brief: Isofol Medical AB- First Patient In Australia Has Initiated Treatment In Global Phase 3 Agent Study
Brief: Patent Approved In Japan For Isofol's Drug Candidate Arfolitixorin
Brief: Isofol Medical AB (Publ) Says Patent Detecting How Patients Respond To Folate-Based Cancer Treatment Approved In USA
Brief: Isofol Medical: Global Phase III Of Agent Study To Start In Australia
Brief: Isofol Medical Appoints Jarl Ulf Jungnelius As New CEO
Brief: Isofol Medical Q3 Net Loss Widens To SEK 42.0 Mln
Brief: Isofol Medical Gets Positive Feedback From PMDA In Japan